• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

    2/13/24 4:00:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Valantine Hannah

    (Last) (First) (Middle)
    C/O BRIDGEBIO PHARMA, INC.
    3160 PORTER DR., SUITE 250

    (Street)
    PALO ALTO CA 94304

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BridgeBio Pharma, Inc. [ BBIO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/28/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/28/2021 P 1,891 A $13.18 1,891 I By Spouse
    Common Stock 12/28/2021 P 1,542 A $12.68 3,433 I By Spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Brian C. Stephenson, Attorney-in-Fact 02/13/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    7/21/2025$66.00Buy
    Truist
    7/14/2025$70.00Buy
    Jefferies
    7/9/2025$60.00Perform → Outperform
    Oppenheimer
    6/17/2025$49.00Outperform
    Wolfe Research
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    9/4/2024$46.00Overweight
    Piper Sandler
    More analyst ratings

    $BBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

      SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 7:49:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 4:31:44 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 4:31:30 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on BridgeBio Pharma with a new price target

      Truist initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $66.00

      7/21/25 8:31:03 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on BridgeBio Pharma with a new price target

      Jefferies initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $70.00

      7/14/25 8:47:47 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BridgeBio Pharma from Perform to Outperform and set a new price target of $60.00

      7/9/25 8:08:10 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

      - By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU - Only ~20% of individuals with genetic variants linked to ADH1 were found to have an established diagnosis, highlighting a major gap in disease recognition and care - Nine novel gain-of-function CASR variants were identified, which were associated with a symptom burden consistent with the known clinical presentation of ADH1 - The findings show an allelic series, indic

      7/23/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

      PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will b

      7/22/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

      Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

      7/11/25 7:43:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

      Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

      11/25/24 8:41:11 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:49:25 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:46:18 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      2/13/24 4:00:10 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

      7/23/24 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

      The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

      5/2/24 7:00:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

      PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

      10/25/21 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Kumar Neil sold $3,410,450 worth of shares (80,000 units at $42.63) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/3/25 4:30:19 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Viking Global Investors Lp sold $154,000,000 worth of shares (3,500,000 units at $44.00) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/1/25 7:48:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Homcy Charles J gifted 20,000 shares, decreasing direct ownership by 2% to 1,216,674 units (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:54:20 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      11/6/24 5:04:05 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      9/17/24 6:41:54 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      8/20/24 8:42:04 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Financials

    Live finance-specific insights

    See more
    • BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

      PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will b

      7/22/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a

      4/22/25 7:30:37 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

      - As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first

      2/20/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care